Gilead Extends Arcellx Tender Offer to April 24; Low Initial Tender Rate Reported

summarizeSummary

Gilead Sciences has extended its tender offer for Arcellx, Inc. until April 24, 2026, with only 7.5% of shares tendered so far, while also providing updates on regulatory approvals and new shareholder lawsuits.

check_boxKey Events · M&A and Partnerships · ACLX

• Tender Offer Extended

  Gilead Sciences has extended the expiration date of its tender offer for Arcellx shares to April 24, 2026, from the previous April 2, 2026 deadline.

• Low Initial Tender Rate

  As of March 31, 2026, only approximately 7.5% of Arcellx's outstanding shares have been validly tendered, indicating a slow initial uptake by shareholders.

• Regulatory Progress

  The HSR Act waiting period has expired, and German antitrust review is not required. Notifications have been submitted to Austrian and Australian competition authorities.

• Shareholder Lawsuits Filed

  Two new lawsuits and sixteen demand letters have been filed by purported shareholders, alleging materially incomplete and misleading disclosures related to the acquisition.

auto_awesomeAnalysis · ACLX · Life Sciences

This SC TO-T/A filing provides an important update on the ongoing acquisition of Arcellx by Gilead Sciences. The extension of the tender offer deadline to April 24, 2026, is a procedural step, likely to allow more time for shareholders to tender their shares and for remaining regulatory approvals to be secured. The reported 7.5% tender rate as of March 31, 2026, is notably low, which could indicate some shareholder hesitation or a belief in the potential value of the contingent value right (CVR). Investors should monitor future tender rates and any further extensions. The disclosure of new shareholder lawsuits alleging disclosure deficiencies is a common occurrence in M&A transactions and typically results in additional disclosures rather than deal termination.